1. Klibanski A, Adams-Campbell L, Bassford T, et al. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285(6): 785–95.
2. Svedbom A, Hernlund E, Ivergård M, et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 2013; 8(137): 35–42.
3. Lakatos P, Takacs I, Marton I, et al. A retrospective longitudinal database study of persistence and compliance with treatment of osteoporosis in Hungary. Calcif Tissue Int 2016; 98(3): 215–25.
4. Fuksa L, Vytrisalova M. Adherence to denosumab in the treatment of osteoporosis and its utilization in the Czech Republic. Curr Med Res Opin 2015; 31(9): 1645–53.
5. Kim SC, Kim DH, Mogun H, et al. Impact of the U.S. Food and Drug Administration's safety-related announcements on the use of bisphosphonates after hip fracture. J Bone Miner Res 2016; 31(8): 1536–40.
6. Levy HB. Polypharmacy reduction strategies: Tips on incorporating American Geriatrics Society Beers and Screening Tool of older people's prescriptions criteria. Clin Geriatr Med 2017; 33(2): 177–87.
7. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56(3): M146-56.
8. Tchkonia T, Zhu Y, van Deursen J, et al. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest 2013; 123(3): 966–72.
9. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965; 37: 614–36.
10. Zhao J, Fuhrmann-Stroissnigg H, Gurkar AU, et al. Quantitative analysis of cellular senescence in culture and in vivo. Curr Protoc Cytom 2017; 79: 9.51.1-9.51.25.
11. Kim HN, Chang J, Shao L, et al. DNA damage and senescence in osteoprogenitors expressing Osx1 may cause their decrease with age. Aging Cell 2017; 16(4): 693–703.
12. Farr JN, Fraser DG, Wang H, et al. Identification of senescent cells in the bne microenvironment. J Bone Miner Res 2016; 31(11): 1920–9.
13. Piemontese M, Almeida M, Robling AG, et al. Old age causes de novo intracortical bone remodeling and porosity in mice. JCI Insight 2017; 2(17):e93771.
14. Endo T. Molecular mechanisms of skeletal muscle development, regeneration, and osteogenic conversion. Bone 2015; 80: 2–13.
15. Lemos DR, Eisner C, Hopkins CI, et al. Skeletal muscle-resident MSCs and bone formation. Bone 2015; 80: 19–23.
16. Brotto M, Bonewald L. Bone and muscle: Interactions beyond mechanical. Bone 2015; 80: 109–14.
17. Ferretti JL, Capozza RF, Cointry GR, et al. Gender-related differences in the relationship between densitometric values of whole-body bone mineral content and lean body mass in humans between 2 and 87 years of age. Bone 1998; 22(6): 683–90.
18. Ethgen O, Beaudart C, Buckinx F, et al. The future prevalence of sarcopenia in Europe: A claim for publichealth action. Calcif Tissue Int 2017; 100(3): 229–34.
19. Trajanoska K, Schoufour JD, Darweesh SK, et al. Sarcopenia and its clinical correlates in the general population: The Rotterdam Study. J Bone Miner Res 2018; 33(7): 1209-18.
20. Rosa J, Šenk F, Palička V. Diagnostika a léčba postmenopauzální osteoporózy. Stanovisko Společnosti pro metabolická onemocnění skeletu ČLS JEP 2015 Osteologicky Bull 2016; 20(4): 150–68.
21. Uchiyama S, Ikegami S, Kamimura M, et al. The skeletal muscle cross sectional area in long-term bisphosphonate users is smaller than that of bone mineral density-matched controls with increased serum pentosidine concentrations. Bone 2015; 75: 84–7.
22. Farr JN, Xu M, Weivoda MM, et al. Targeting cellular senescence prevents age-related bone loss in mice. Nat Med 2017; 23(9): 1072–9.
23. Haugeberg G, Helgetveit KB, Forre O, et al. Generalized bone loss in early rheumatoid arthritis patients followed for ten years in the biologic treatment era. BMC Musculoskelet Disord 2014; 15: 289.
24. Štěpán J. Osteoporóza, chronický zánět, mikrobiom a estrogeny. Remedia 2018; 28(1): 28–34.
25. Chang J, Liu F, Lee M, et al. NF-kappaB inhibits osteogenic differentiation of mesenchymal stem cells by promoting beta-catenin degradation. Proc Natl Acad Sci U S A 2013; 110(23): 9469–74.
26. Yeremenko N, Zwerina K, Rigter G, et al. Tumor necrosis factor and interleukin-6 differentially regulate Dkk-1 in the inflamed arthritic joint. Arthritis Rheumatol 2015; 67(8): 2071–5.
27. Tyagi AM, Mansoori MN, Srivastava K, et al. Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-alpha antibodies. J Bone Miner Res 2014; 29(9):1981–92.
28. Hubbard RE, Woodhouse KW. Frailty, inflammation and the elderly. Biogerontology 2010; 11(5): 635–41.
29. Fulop T, Larbi A, Witkowski JM, et al. Aging, frailty and age-related diseases. Biogerontology 2010; 11(5): 547–63.
30. Bano G, Trevisan C, Carraro S, et al. Inflammation and sarcopenia: A systematic review and meta-analysis. Maturitas 2017; 96: 10–5.
31. Aleman H, Esparza J, Ramirez FA, et al. Longitudinal evidence on the association between interleukin-6 and C-reactive protein with the loss of total appendicular skeletal muscle in free-living older men and women. Age Ageing 2011; 40(4): 469–75.
32. Geffken DF, Cushman M, Burke GL, et al. Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol 2001; 153(3): 242–50.
33. Pfeifer M, Sinaki M, Geusens P, Boonen S, et al. Musculoskeletal rehabilitation in osteoporosis: a review. J Bone Miner Res 2004; 19(8): 1208–14.
34. Forsen L, Bjorndal A, Bjartveit K, et al. Interaction between current smoking, leanness, and physical inactivity in the prediction of hip fracture. J Bone Miner Res 1994; 9(11): 1671–8.
35. Stattin K, Michaelsson K, Larsson SC, et al. Leisure-time physical activity and risk of fracture: A cohort study of 66,940 men and women. J Bone Miner Res 2017; 32(8): 1599–606.
36. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014; 146(6): 1489–99.
37. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell 2014; 157(1): 121–41.
38. Taneja V. Microbiome in 2016: T follicular helper cells and the gut microbiome in arthritis. Nat Rev Rheumatol 2017; 13(2): 72–4.
39. Weitzmann MN. The role of inflammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis. Scientifica (Cairo) 2013; 2013: 125705.
40. Li JY, Chassaing B, Tyagi AM, et al. Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics. J Clin Invest 2016;126(6): 2049–63.
41. Byberg L, Bellavia A, Larsson SC, et al. Mediterranean Diet and Hip Fracture in Swedish Men and Women. J Bone Miner Res 2016; 31(12): 2098–105.
42. Orchard T, Yildiz V, Steck SE, et al. Dietary inflammatory index, bone mineral density, and risk of fracture in postmenopausal women: Results from the Women's Health Initiative. J Bone Miner Res 2017; 32(5): 1136–46.
43. Jafarnejad S, Djafarian K, Fazeli MR, et al. Effects of a Multispecies Probiotic Supplement on Bone Health in Osteopenic Postmenopausal Women: A Randomized, Double-blind, Controlled Trial. J Am Coll Nutr 2017; 36(7): 497–506.
44. Slevin MM, Allsopp PJ, Magee PJ, et al. Supplementation with calcium and short-chain fructo-oligosaccharides affects markers of bone turnover but not bone mineral density in postmenopausal women. J Nutr 2014; 144(3): 297–304.
45. Puth MT, Klaschik M, Schmid M, et al. Prevalence and comorbidity of osteoporosis- a cross-sectional analysis on 10,660 adults aged 50 years and older in Germany. BMC Musculoskelet Disord 2018; 19(1): 144.
46. Schett G, Kiechl S, Weger S, et al. High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med 2006; 166(22): 2495–501.
47. Wahlin-Larsson B, Carnac G, Kadi F. The influence of systemic inflammation on skeletal muscle in physically active elderly women. Age (Dordr) 2014; 36(5): 9718.
48. Mikkelsen UR, Couppe C, Karlsen A, et al. Life-long endurance exercise in humans: circulating levels of inflammatory markers and leg muscle size. Mech Ageing Dev 2013; 134(11-12): 531–40.
49. Watson SL, Weeks BK, Weis LJ, et al. High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial. J Bone Miner Res 2018; 33(2): 211–20.
50. Watson SL, Weeks BK, Weis LJ, et al. Heavy resistance training is safe and improves bone, function, and stature in postmenopausal women with low to very low bone mass: novel early findings from the LIFTMOR trial. Osteoporos Int 2015; 26(12): 2889–94.
51. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39(4): 412–23.
52. American College of Sports Medicine. ACSM’s Guidelines for Exercise Testing and Prescription. 10 ed. Philadelphia: Lippincott Williams & Wilkins; 2018.